# Research Advances on the Immune Evasion Mechanisms of Disseminated Tumor Cells and Their Roles in Cancer Metastasis

**Authors:** Zujun QUE, Bin LUO, Jianhui TIAN

PMC · DOI: 10.3779/j.issn.1009-3419.2025.101.23 · Chinese Journal of Lung Cancer · 2025-12-20

## TL;DR

This paper reviews how disseminated tumor cells evade the immune system to promote cancer metastasis and explores new insights combining traditional Chinese medicine theories.

## Contribution

The paper innovatively integrates traditional Chinese medicine concepts with modern immunology to explain DTCs' immune evasion.

## Key findings

- DTCs use antigen presentation defects to avoid immune detection.
- Immunosuppressive cells like Tregs and MDSCs help DTCs create a protective microenvironment.
- Metabolic reprogramming in DTCs weakens immune cell function.

## Abstract

肿瘤转移是导致癌症患者死亡的首要原因，而播散肿瘤细胞（disseminated tumor cells, DTCs）作为转移级联反应中的关键“种子”，其命运直接决定了转移的成败。DTCs从原发灶脱落并定殖于远处靶器官后，常进入一种长期休眠状态，随后通过复杂的免疫逃逸机制突破免疫监视，从休眠态激活为增殖态，最终形成临床可评估的转移灶。深入理解DTCs的免疫逃逸机制对于揭示肿瘤转移的本质和开发有效的抗转移策略至关重要。本文系统综述了DTCs免疫逃逸机制的最新研究进展，重点围绕三大核心机制展开：抗原呈递缺陷、免疫抑制微环境的形成以及代谢重编程介导的免疫抑制。具体而言，DTCs通过下调主要组织相容性复合体I类（major histocompatibility complex class-I, MHC-I）分子表达实现“免疫隐身”；主动招募调节性T细胞（regulatory T cells, Tregs）、髓源性抑制细胞（myeloid-derived suppressor cells, MDSCs）等免疫抑制性细胞，构建局部“防护盾”；并通过重塑糖、氨基酸及脂质代谢，从能量与物质层面削弱效应免疫细胞功能。在此基础上，本文创新性地结合中医“正虚伏毒”与“转移态”理论，阐释机体正气盛衰与DTCs休眠-觉醒转换之间的动态病机关系，为从整体调控角度认识转移过程提供了新视角。最后，文章展望了针对DTCs免疫逃逸的多靶点联合治疗策略，以及单细胞测序、空间转录组等新技术在该领域的应用前景，以期为未来抗转移研究的深入与临床转化提供重要参考。

Major immunosuppressive cells in the DTCs microenvironment: their roles and key effector molecules

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 100126861] {aka Akt, PKB}, FTO (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 100127165], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 396696], SGK1 (serum/glucocorticoid regulated kinase 1) [NCBI Gene 100625739], KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 396737] {aka NKG2D}, IL10 (Interleukin 10 level) [NCBI Gene 103158318], HRG (histidine rich glycoprotein) [NCBI Gene 100152095], VEGFA (vascular endothelial growth factor A) [NCBI Gene 397157] {aka VEGF}, AHR (aryl hydrocarbon receptor) [NCBI Gene 396654], LDHA (lactate dehydrogenase A) [NCBI Gene 407245] {aka LDH-A, LDH-M}, PTEN (phosphatase and tensin homolog) [NCBI Gene 100156264], IL6 (interleukin 6) [NCBI Gene 399500] {aka IL-6}, signal transducer and activator of transcription 1 [NCBI Gene 100738308], IL1B (interleukin 1 beta) [NCBI Gene 397122] {aka IL1B1}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 396668] {aka MIP-1BETA, MIP1b, SCY4A}, SFRP1 (secreted frizzled related protein 1) [NCBI Gene 100621622], EHMT2 (euchromatic histone lysine methyltransferase 2) [NCBI Gene 100124382] {aka BAT8, G9a}, IRF1 (interferon regulatory factor 1) [NCBI Gene 396611] {aka IRF-1}, ALDOC (aldolase, fructose-bisphosphate C) [NCBI Gene 100512013], CXADR (CXADR Ig-like cell adhesion molecule) [NCBI Gene 397333] {aka CAR}, CD4 (CD4 molecule) [NCBI Gene 404704], ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1) [NCBI Gene 397298] {aka ATP-DPH, CD39}, NLRC5 (NLR family CARD domain containing 5) [NCBI Gene 100135667] {aka NOD27, NOD4}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 397286], SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 100623101], CSF2 (colony stimulating factor 2) [NCBI Gene 397208] {aka GM-CSF}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 397087] {aka Opn}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 396880] {aka AMCF-I, IL8}, TNF (tumor necrosis factor) [NCBI Gene 397086] {aka TNFSF2, TNFa}, IL10 (interleukin 10) [NCBI Gene 397106] {aka CSIF, IL-10}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 100217389] {aka STING, TMEM173}, NPM1 (nucleophosmin 1) [NCBI Gene 100525313], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 733648], SCUBE2 (signal peptide, CUB domain and EGF like domain containing 2) [NCBI Gene 100519613], MIF (macrophage migration inhibitory factor) [NCBI Gene 397412], SIGLEC15 (sialic acid binding Ig like lectin 15) [NCBI Gene 100518460], NOS2 (nitric oxide synthase 2) [NCBI Gene 396859] {aka INOS, NOS2a}, EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 100625497], CALR (calreticulin) [NCBI Gene 100381266] {aka CRP55, Calregulin, ERp60, HACBP}, EMILIN1 (elastin microfibril interfacer 1) [NCBI Gene 100523665], STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 396655], LOC396821 (inducible nitric-oxide synthase) [NCBI Gene 396821], CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 396613] {aka RANTES, SCYA5, SIS-delta}, TDO2 (tryptophan 2,3-dioxygenase) [NCBI Gene 100301559] {aka TDO}, FGF19 (fibroblast growth factor 19) [NCBI Gene 100518950], Fbxw7 [NCBI Gene 100739813], FASN (fatty acid synthase) [NCBI Gene 397561], IFNG (interferon gamma) [NCBI Gene 396991], CD274 (CD274 molecule) [NCBI Gene 574058] {aka PDL1}, PDCD1 (programmed cell death 1) [NCBI Gene 100533201], MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 448810] {aka c-Myc, c-Myc-a, c-Myc-b}, WNT5A (Wnt family member 5A) [NCBI Gene 100627056], CXCL2 (chemokine (C-X-C motif) ligand 2) [NCBI Gene 414904] {aka GRO2, GROB, MIP2, MIP2A, SCYB2}, CDK5 (cyclin dependent kinase 5) [NCBI Gene 733700], CD47 (CD47 molecule) [NCBI Gene 397042] {aka CD47/IAP}, elastin [NCBI Gene 100620140], FGFR4 (fibroblast growth factor receptor 4) [NCBI Gene 100127133], JAK2 (Janus kinase 2) [NCBI Gene 397201], CTNNB1 (catenin beta 1) [NCBI Gene 397657], SHH (sonic hedgehog signaling molecule) [NCBI Gene 100512749]
- **Diseases:** neutrophil extracellular trap (MESH:C536657), Cancer Metastasis (MESH:D009369), toxicity (MESH:D064420), metastatic (MESH:D000092182), Tumor metastasis (MESH:D009362)
- **Chemicals:** KYN (MESH:D007737), glucose (MESH:D005947), ROS (MESH:D017382), lipid (MESH:D008055)
- **Mutations:** C-C        5, arginine/tryptophan

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12972579/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12972579/full.md

---
Source: https://tomesphere.com/paper/PMC12972579